Kaliyadan F,Nambiar A,Vijayaraghavan S. .2013 .Androgenetic alopecia: an update. Indian J Dermatol Venereol Leprol, 79(5) : 613.
Wang TL,Zhou C,Shen YW,Wang XY,Ding XL,Tian S,Liu Y,Peng GH,Xue SQ,Zhou JE,Wang RL .2010 .Prevalence of androgenetic alopecia in China: a community-based study in six cities. Br J Dermatol, 162(4) : 843-7.
Sadiq S,Naveed T,Naveed S,Minhas IJ,Khan BM,Sadiq S. .2022 .Using Skindex-29 Scale to Assess The Impact of Androgenetic/Patterned Hair Loss on Quality of Life of Patients in Pakistan. Pak Armed Forces Med, 72(1) : 42-6.
Blumeyer A,Tosti A,Messenger A,Reygagne P,Del Marmol V,Spuls PI,Trakatelli M,Finner A,Kiesewetter F,Trüeb R,Rzany B .2011 .Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges, 9(Suppl 6) : S1-57.
Lolli F,Pallotti F,Rossi A,Fortuna MC,Caro G,Lenzi A,Sansone A,Lombardo F .2017 .Androgenetic alopecia: a review. Endocrine, 57(1) : 9-17.
Matsumura H,Mohri Y,Binh NT,Morinaga H,Fukuda M,Ito M,Kurata S,Hoeijmakers J,Nishimura EK .2016 .Hair follicle aging is driven by transepidermal elimination of stem cells via COL17A1 proteolysis. Science, 351(6273) : aad4395.
Rathnayake D,Sinclair R .2010 .Male androgenetic alopecia. Expert Opin Pharmacother, 11(8) : 1295-304.
Rossi A,Anzalone A,Fortuna MC,Caro G,Garelli V,Pranteda G,Carlesimo M. .2016 .Multitherapies in androgenetic alopecia: Review and clinical experiences. Dermatol Ther, 29(6) : 424-32.
Okeigwe I .2014 .-Alpha reductase deficiency: a 40-year retrospective review. Curr Opin Endocrinol Diabetes Obes, 21(6) : 483-7.
Leiros GJ,Attorresi AI,Balaña ME .2012 .Hair follicle stem cell differentiation is inhibited through cross-talk between Wnt/β-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia. Br J Dermatol, 166(5) : 1035-42.
Kaliyadan F,Nambiar A,Vijayaraghavan S. .2013 .Androgenetic alopecia: an update. Indian J Dermatol Venereol Leprol, 79(5) : 613.
Sattur SS,Sattur IS,Trüeb RM,Tobin DJ .2010 .Present and Future Treatments of Androgenic Alopecia. Aging Hair, : 263-77.
Hsu CL,Liu JS,Lin TW,Chang YH,Kuo YC,Lin AC,Ting HJ,Pang ST,Lee LY,Ma WL,Lin CC .2017 .Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress ARmediated prostate cancer growth via peptide and chemical screening. Oncotarget, 8(41) : 69508.
Lee NE,Park SD,Hwang H,Choi SH,Lee RM,Nam SM,Choi JH,Rhim H,Cho IH,Kim HC,Hwang SH .2020 .Effects of a gintoninenriched fraction on hair growth: an in vitro and in vivo study. J Ginseng Res, 44(1) : 168-77.
Shorter K,Farjo NP,Picksley SM .2008 .Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J, 22(6) : 1725-36.
Kwack MH,Kang BM,Kim MK,Kim JC,Sung YK .2011 .Minoxidil activates β-catenin pathway in human dermal papilla cells: A possible explanation for its anagen prolongation effect. J Dermatol Sci, 62(3) : 154-9.
Messenger AG,Rundegren J .2004 .Minoxidil: mechanisms of action on hair growth. Br J Dermatol, 150(2) : 186-94.
Wirya CT,Wu W,Wu K .2017 .Classification of male-pattern hair loss. Int J Trichol, 9(3) : 95.
Shankar DK,Chakravarthi M,Shilpakar R .2009 .Male androgenetic alopecia: populationbased study in 1,005 subjects. Int J Trichol, 1(2) : 131.
Nestor MS,Ablon G,Gade A,Han H,Fischer DL H .2021 .Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol, 20(12) : 3759-81.
Rundegren J. .2004 .A one-year observational study with minoxidil 5% solution in Germany: results of independent efficacy evaluation by physicians and patients 1. J Am Acad Dermatol, 50(3 Suppl)) : P91.
Ghonemy S,Alarawi A,Bessar H. Efficacy .2021 .and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. J Dermatolog Treat, 32(2) : 236-41.
Arca E,Açıkgöz G,Taştan HB,Köse O,Kurumlu Z. .2004 .An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology, 209(2) : 117-25.
Balasundaram M,Kumari R .2023 .Efficacy of autologous Platelet-rich plasma therapy versus topical Minoxidil in men with moderate androgenetic alopecia: A randomized open-label trial. J Dermatolog Treat, 34(1) : 2182618.
Eslahi E,Hashemi N,Shamaei S. .2022 .Effectiveness of the active ingredients (Capixyl, Procapil, and rosemary extract) of the Trust J tonic for the treatment of androgenetic alopecia in comparison to minoxidil. Our Dermatol Online, 13(4) : 346-51.
Karaca N,Akpolat ND .2019 .A comparative study between topical 5% minoxidil and topical "Redensyl, Capixyl, and Procapil" combination in men with androgenetic alopecia. J Cosmetol Trichol, 150370987 : .
Leiros GJ,Attorresi AI,Balaña ME .2012 .Hair follicle stem cell differentiation is inhibited through cross-talk between Wnt/β-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia. Br J Dermatol, 166(5) : 1035-42.